Literature DB >> 3493904

Hypotensive effects of ovine and human corticotrophin-releasing factors in man.

A R Hermus, G F Pieters, J J Willemsen, H A Ross, A G Smals, T J Benraad, P W Kloppenborg.   

Abstract

The haemodynamic effects of i.v. bolus injections of 100 and 200 micrograms ovine CRF and human CRF in man have been compared. Neither ovine CRF 100 micrograms nor human CRF 100 micrograms caused a significant change in blood pressure, although the pulse rate was increased in all the subjects tested. The mean maximum increase in pulse rate after human CRF was almost twice that after ovine CRF (21 vs 12 beats X min-1; p less than 0.05). After 200 micrograms ovine CRF in all subjects the diastolic blood pressure declined gradually from 77 mm Hg to a nadir of 67 mm Hg at 22 min (p less than 0.002). After 200 micrograms human CRF diastolic blood pressure fell from 78 mm Hg to a nadir of 61 mm Hg at 6 min (p less than 0.002); the fall after human CRF was significantly greater than after ovine CRF (p less than 0.05). After 200 micrograms ovine CRF there was a slight increase in pulse rate lasting for 6 min, and after 200 micrograms human CRF there was a marked (reflex) tachycardia for 30 min. Only after the highest dose of human CRF did a slight increase in systolic blood pressure occur. The haemodynamic effects of both doses of human CRF were accompanied by significant increases in plasma noradrenaline concentrations, which were significantly greater after the higher dose.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3493904     DOI: 10.1007/BF00606625

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  18 in total

1.  Safety of corticotropin-releasing factor.

Authors:  A Hermus; J M Raemaekers; G F Peters; A K Bartelink; A G Smals; P W Kloppenborg
Journal:  Lancet       Date:  1983-07-09       Impact factor: 79.321

2.  Effects of synthetic ovine CRF on ACTH, cortisol and blood pressure in sheep.

Authors:  N H Kalin; J C Gonder; S E Shelton
Journal:  Peptides       Date:  1983 Mar-Apr       Impact factor: 3.750

3.  Corticotropin-releasing factor administered intraventricularly to rhesus monkeys.

Authors:  N H Kalin; S E Shelton; G W Kraemer; W T McKinney
Journal:  Peptides       Date:  1983 Mar-Apr       Impact factor: 3.750

4.  Corticotropin-releasing factor (CRF): central effects on mean arterial pressure and heart rate in rats.

Authors:  L A Fisher; J Rivier; C Rivier; J Spiess; W Vale; M R Brown
Journal:  Endocrinology       Date:  1982-06       Impact factor: 4.736

5.  Plasma adrenocorticotropin and cortisol responses to ovine corticotropin-releasing factor in patients with adrenocortical insufficiency due to hypothalamic and pituitary disorders.

Authors:  T Tsukada; Y Nakai; T Koh; S Tsujii; M Inada; M Nishikawa; H Shinoda; I Kawai; N Takezawa; H Imura
Journal:  J Clin Endocrinol Metab       Date:  1984-04       Impact factor: 5.958

6.  Amunine (ovine CRF), urotensin I and sauvagine, three structurally-related peptides, produce selective dilation of the mesenteric circulation.

Authors:  K L MacCannell; K Lederis; P L Hamilton; J Rivier
Journal:  Pharmacology       Date:  1982       Impact factor: 2.547

7.  Comparison of the biologic actions of corticotropin-releasing factor and sauvagine.

Authors:  M R Brown; L A Fisher; J Spiess; J Rivier; C Rivier; W Vale
Journal:  Regul Pept       Date:  1982-07

8.  Human corticotropin-releasing factor in man: pharmacokinetic properties and dose-response of plasma adrenocorticotropin and cortisol secretion.

Authors:  T H Schürmeyer; P C Avgerinos; P W Gold; W T Gallucci; T P Tomai; G B Cutler; D L Loriaux; G P Chrousos
Journal:  J Clin Endocrinol Metab       Date:  1984-12       Impact factor: 5.958

9.  Radioenzymatic assay of plasma adrenaline and noradrenaline: evidence for a catechol-O-methyltransferase (COMT) inhibiting factor associated with essential hypertension.

Authors:  J J Hoffmann; J J Willemsen; T Thien; T J Benraad
Journal:  Clin Chim Acta       Date:  1982-11-10       Impact factor: 3.786

10.  The corticotropin-releasing factor stimulation test. An aid in the evaluation of patients with Cushing's syndrome.

Authors:  G P Chrousos; H M Schulte; E H Oldfield; P W Gold; G B Cutler; D L Loriaux
Journal:  N Engl J Med       Date:  1984-03-08       Impact factor: 91.245

View more
  6 in total

Review 1.  Placental stress factors and maternal-fetal adaptive response: the corticotropin-releasing factor family.

Authors:  Pasquale Florio; Filiberto M Severi; Pasquapina Ciarmela; Giovina Fiore; Giulia Calonaci; Angelica Merola; Claudio De Felice; Marco Palumbo; Felice Petraglia
Journal:  Endocrine       Date:  2002-10       Impact factor: 3.633

2.  Relaxing actions of corticotropin-releasing factor on rat resistance arteries.

Authors:  S Lei; R Richter; M Bienert; M J Mulvany
Journal:  Br J Pharmacol       Date:  1993-04       Impact factor: 8.739

3.  CRF2 receptors are highly expressed in the human cardiovascular system and their cognate ligands urocortins 2 and 3 are potent vasodilators.

Authors:  Katherine E Wiley; Anthony P Davenport
Journal:  Br J Pharmacol       Date:  2004-09-20       Impact factor: 8.739

4.  Intra- and extracerebral blood flow changes and flushing after intravenous injection of human corticotropin-releasing hormone.

Authors:  A Kübler; G Rothacher; V A Knappertz; G Krämer; M Nink; J Beyer; H Lehnert
Journal:  Clin Investig       Date:  1994-05

5.  Impact of corticotropin-releasing hormone on gastrointestinal motility and adrenocorticotropic hormone in normal controls and patients with irritable bowel syndrome.

Authors:  S Fukudo; T Nomura; M Hongo
Journal:  Gut       Date:  1998-06       Impact factor: 23.059

6.  Clinical perspectives of urocortin and related agents for the treatment of cardiovascular disease.

Authors:  Keiichi Ikeda; Kouki Fujioka; Yoshinobu Manome; Katsuyoshi Tojo
Journal:  Int J Endocrinol       Date:  2012-04-03       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.